24 h | 48 h | |||||
---|---|---|---|---|---|---|
Control | CX | TBI | Control | CX | TBI | |
Total P450 (nmol/mg) | 0.77 ± 0.07 | 0.69 ± 0.061-150 | 0.67 ± 0.041-150 | 0.63 ± 0.06 | 0.64 ± 0.09 | 0.67 ± 0.04 |
Liver 6OH-CHZ formation rate (nmol/mg)/min | 1.68 ± 0.18 | 1.76 ± 0.33 | 1.52 ± 0.21 | 1.39 ± 0.19 | 1.33 ± 0.13 | 1.03 ± 0.251-150 |
Kidney 6OH-CHZ formation rate (nmol/mg)/min | 0.081 ± 0.031 | 0.106 ± 0.011 | 0.125 ± 0.0111-150 | 0.108 ± 0.012 | 0.117 ± 0.017 | 0.121 ± 0.020 |
Cortex 6OH-CHZ formation rate (pmol/mg)/min | 1.22 ± 0.69 | 1.32 ± 0.48 | 0.74 ± 0.62 | N.A. | N.A. | N.A. |
Liver CYP2E1 protein content (% Control) | N.A. | N.A. | N.A. | 100 ± 12.2 | 91.0 ± 13.8 | 87.3 ± 22.8 |
Kidney CYP2E1 protein content (% Control) | 100 ± 28.8 | 102.4 ± 32.6 | 117.0 ± 18.4 | N.A. | N.A. | N.A. |
Results shown are mean ± standard deviation.
6OH-CHZ, 6-hydroxychlorzoxazone; N.A., not assessed.
↵1-150 Statistically significant differences from control (one way analysis of variance with Tukey's post hoc analysis, p < 0.05).